Last reviewed · How we verify
Prevention of migraine attacks in adults — Treatment Landscape & Competitive Intelligence
2 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Rimegepant 75mg every other day dosing | rimegepant-75mg-every-other-day-dosing | Pfizer | calcitonin gene-related peptide receptor antagonist | calcitonin gene-related peptide receptor | ||
| Rimegepant 75mg daily dosing | rimegepant-75mg-daily-dosing | Pfizer | calcitonin gene-related peptide receptor antagonist | calcitonin gene-related peptide receptor |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- Pfizer · 2 drugs in Prevention of migraine attacks in adults
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Prevention of migraine attacks in adults:
- Prevention of migraine attacks in adults treatment updates — RSS
- Prevention of migraine attacks in adults treatment updates — Atom
- Prevention of migraine attacks in adults treatment updates — JSON
Cite this brief
Drug Landscape (2026). Prevention of migraine attacks in adults — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/prevention-of-migraine-attacks-in-adults. Accessed 2026-06-10.
Related
- Prevention of migraine attacks in adults full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing